Perceptive Advisors Invests $49.9M in Solid Biosciences Private Placement, Boosting Stake to 12.9%
SLDB has more than doubled off its 52-week low of $2.41 on elevated volume (3.4× avg).
Summary
Perceptive Advisors disclosed a $49.9 million investment in Solid Biosciences' recent private placement, acquiring pre-funded warrants and increasing its beneficial ownership to 12.9%.
Key Events · Ownership and Investor Activity · SLDB
-
Major Investment in Private Placement
Perceptive Advisors, through its Master Fund, acquired 8,912,655 pre-funded warrants for $49.9 million in Solid Biosciences' private placement, which closed on March 9, 2026.
-
Increased Beneficial Ownership
This investment increases Perceptive Advisors' beneficial ownership in Solid Biosciences to 12.9% of the outstanding common stock.
-
Warrant Exercise Limitation
The pre-funded warrants include a beneficial ownership limitation, preventing exercise if it would result in ownership exceeding 9.99%.
-
Follows Previously Announced Capital Raise
This disclosure details a significant participant in the $240 million private placement announced by Solid Biosciences on March 6, 2026, and follows other investor disclosures related to the same event.
Analysis · SLDB · Life Sciences
This Schedule 13D/A filing reveals Perceptive Advisors' substantial participation in Solid Biosciences' recently announced $240 million private placement. The $49.9 million investment, through the acquisition of pre-funded warrants, significantly increases Perceptive's beneficial ownership to 12.9%. While the warrants have a 9.99% exercise limitation, this large investment by a prominent life sciences investor signals strong institutional confidence in Solid Biosciences, especially following the positive clinical data reported on March 11, 2026. This capital infusion, detailed by a major investor, strengthens the company's financial position and extends its cash runway.
How filings like this one have moved
In the 30 days to Sep 22, 2026, 34.8% of the 1044 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SLDB was trading at $8.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $601.1M. The 52-week trading range was $2.41 to $8.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.